These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28428880)

  • 1. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
    Cabel L; Loir E; Gravis G; Lavaud P; Massard C; Albiges L; Baciarello G; Loriot Y; Fizazi K
    J Immunother Cancer; 2017; 5():31. PubMed ID: 28428880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
    Fizazi K; Drake CG; Beer TM; Kwon ED; Scher HI; Gerritsen WR; Bossi A; den Eertwegh AJMV; Krainer M; Houede N; Santos R; Mahammedi H; Ng S; Danielli R; Franke FA; Sundar S; Agarwal N; Bergman AM; Ciuleanu TE; Korbenfeld E; Sengeløv L; Hansen S; McHenry MB; Chen A; Logothetis C;
    Eur Urol; 2020 Dec; 78(6):822-830. PubMed ID: 32811715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
    Lheureux S; Butler MO; Clarke B; Cristea MC; Martin LP; Tonkin K; Fleming GF; Tinker AV; Hirte HW; Tsoref D; Mackay H; Dhani NC; Ghatage P; Weberpals J; Welch S; Pham NA; Motta V; Sotov V; Wang L; Karakasis K; Udagani S; Kamel-Reid S; Streicher HZ; Shaw P; Oza AM
    JAMA Oncol; 2018 Jul; 4(7):e173776. PubMed ID: 29145543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for the use of ipilimumab in treating advanced prostate cancer.
    Wei XX; Fong L; Small EJ
    Expert Opin Biol Ther; 2016; 16(3):421-32. PubMed ID: 26698365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
    Sharma P; Pachynski RK; Narayan V; Fléchon A; Gravis G; Galsky MD; Mahammedi H; Patnaik A; Subudhi SK; Ciprotti M; Simsek B; Saci A; Hu Y; Han GC; Fizazi K
    Cancer Cell; 2020 Oct; 38(4):489-499.e3. PubMed ID: 32916128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
    Chalmers AW; Patel S; Boucher K; Cannon L; Esplin M; Luckart J; Graves N; Van Duren T; Akerley W
    Target Oncol; 2019 Aug; 14(4):417-421. PubMed ID: 31346927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
    Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of rituximab in metastatic castrate-resistant prostate cancer.
    Bindal P; Jalil SA; Holle LM; Clement JM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1509-1511. PubMed ID: 30092742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
    Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
    Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Shenderov E; Boudadi K; Fu W; Wang H; Sullivan R; Jordan A; Dowling D; Harb R; Schonhoft J; Jendrisak A; Carducci MA; Eisenberger MA; Eshleman JR; Luo J; Drake CG; Pardoll DM; Antonarakis ES
    Prostate; 2021 May; 81(6):326-338. PubMed ID: 33636027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
    Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
    Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
    Ros-Montañá J; Saoudi-Gonzalez N; Ortiz-Velez C; Muñoz-Couselo E
    Melanoma Res; 2020 Apr; 30(2):209-212. PubMed ID: 31348136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
    Saad F; Miller K
    Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
    Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
    Cha E; Small EJ
    Cancer Med; 2013 Apr; 2(2):243-52. PubMed ID: 23634292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
    Beer TM; Kwon ED; Drake CG; Fizazi K; Logothetis C; Gravis G; Ganju V; Polikoff J; Saad F; Humanski P; Piulats JM; Gonzalez Mella P; Ng SS; Jaeger D; Parnis FX; Franke FA; Puente J; Carvajal R; Sengeløv L; McHenry MB; Varma A; van den Eertwegh AJ; Gerritsen W
    J Clin Oncol; 2017 Jan; 35(1):40-47. PubMed ID: 28034081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.